Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Insight Molecular Diagnostics Inc (IMDX)

Insight Molecular Diagnostics Inc (IMDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 112,363
  • Shares Outstanding, K 28,664
  • Annual Sales, $ 1,880 K
  • Annual Income, $ -60,660 K
  • EBIT $ -19 M
  • EBITDA $ -18 M
  • 60-Month Beta 1.35
  • Price/Sales 25.94
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 0.00% (-270.40%)
  • Historical Volatility 114.84%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,191.63% on 03/11/26
  • IV Low 0.00% on 03/19/26
  • Expected Move (DTE 27) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 80
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 360
  • Open Int (30-Day) 301
  • Expected Range 4.26 to 4.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.48
  • Growth Rate Est. (year over year) +208,025.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.91 +9.04%
on 03/19/26
6.19 -31.18%
on 02/27/26
-1.23 (-22.40%)
since 02/20/26
3-Month
3.91 +9.04%
on 03/19/26
7.51 -43.28%
on 02/09/26
-1.15 (-21.26%)
since 12/19/25
52-Week
2.33 +82.83%
on 08/29/25
8.51 -49.94%
on 11/12/25
+0.96 (+29.09%)
since 03/20/25

Most Recent Stories

More News
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference

NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market...

IMDX : 4.26 (+8.67%)
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score

New data supports GraftAssure commercialization efforts Multi-center study featured 249 biopsy-matched patients Proprietary “Combination Model” score outperformed percentage-only measures of...

IMDX : 4.26 (+8.67%)
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission

Three-site reproducibility study completed by Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health Sufficient clinical samples collected to support statistical analysis and FDA submission...

IMDX : 4.26 (+8.67%)
iMDx Announces $26.0 Million Registered Direct Offering

NASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (“iMDx” or the “Company”), today announced that it has entered into definitive agreements...

IMDX : 4.26 (+8.67%)
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring

American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a diagnostic marker, a key feature of iMDx’s flagship GraftAssure TM family of assays...

IMDX : 4.26 (+8.67%)
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced members of its management team will participate in the following investor...

IMDX : 4.26 (+8.67%)
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

Dr. Nick Ioannou brings decades of academia, industry, and clinical experience in organ transplant, nephrology, cardiology, genetics, and oncology NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE)...

IMDX : 4.26 (+8.67%)
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion

GraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian site GraftAssureDx™ FDA IVD approval application 95% complete...

IMDX : 4.26 (+8.67%)
This Biotech Stock Is Up 158% in a Year. What’s Driving It Higher?

Insight Molecular Diagnostics (IMDX) is a precision diagnostics company with disruptive transplant technology and strong recent price momentum. IMDX has surged 158% over the past year and is trading at...

IMDX : 4.26 (+8.67%)
Insight Molecular Diagnostics: Q3 Earnings Snapshot

Insight Molecular Diagnostics: Q3 Earnings Snapshot

IMDX : 4.26 (+8.67%)

Business Summary

Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn.

See More

Key Turning Points

3rd Resistance Point 4.71
2nd Resistance Point 4.48
1st Resistance Point 4.37
Last Price 4.26
1st Support Level 4.04
2nd Support Level 3.81
3rd Support Level 3.70

See More

52-Week High 8.51
Fibonacci 61.8% 6.15
Fibonacci 50% 5.42
Fibonacci 38.2% 4.69
Last Price 4.26
52-Week Low 2.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.